Role of the Inflammasome in Myocardial Infarction

Trends in Cardiovascular Medicine

Volumn 21, Issue 2, 2011, Pages 37-41

  Takahashi, Masafumi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; INFLAMMASOME; INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT;

DRUG TARGETING; FIBROBLAST; HEART INFARCTION; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; INFLAMMASOMES; MYOCARDIAL INFARCTION;

EID: 84860792654     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.02.002     Document Type: Review

References (41)

1. Burckstummer T., Baumann C., Bluml S., et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009, 10:266-272.
2. Calligaris L., Marchetti F., Tommasini A., et al. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 2008, 167:695-696.
3. Cassel S.L., Eisenbarth S.C., Iyer S.S., et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 2008, 105:9035-9040.
4. Chen G.Y., Nunez G. Sterile inflammation: Sensing and reacting to damage. Nat Rev Immunol 2010, 10:826-837.
5. Davis B.K., Wen H., Ting J.P. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011, 29:707-735.
6. Dostert C., Petrilli V., Van Bruggen R., et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320:674-677.
7. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
8. Fernandes-Alnemri T., Yu J.W., Datta P., et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009, 458:509-513.
9. Frangogiannis N.G., Smith C.W., Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res 2002, 53:31-47.
10. Goldbach-Mansky R., Dailey N.J., Canna S.W., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355:581-592.
11. Halle A., Hornung V., Petzold G.C., et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008, 9:857-865.
12. Hoffman H.M., Rosengren S., Boyle D.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364:1779-1785.
13. Hornung V., Ablasser A., Charrel-Dennis M., et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009, 458:514-518.
14. Ippagunta S.K., Malireddi R.K., Shaw P.J., et al. The inflammasome adaptor ASC regulates the function of adaptive immune cells by controlling Dock2-mediated Rac activation and actin polymerization. Nat Immunol 2011, 12:1010-1016.
15. Jennings R.B., Sommers H.M., Smyth G.A., et al. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960, 70:68-78.
16. Kawaguchi M., Takahashi M., Hata T., et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011, 123:594-604.
17. Kuida K., Lippke J.A., Ku G., et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 1995, 267:2000-2003.
18. Kuijk L.M., Govers A.M., Frenkel J., et al. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 2007, 66:1545-1546.
19. Larsen C.M., Faulenbach M., Vaag A., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007, 356:1517-1526.
20. Litt M.R., Jeremy R.W., Weisman H.F., et al. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia: Evidence for neutrophil-mediated reperfusion injury. Circulation 1989, 80:1816-1827.
21. Ma X.L., Tsao P.S., Lefer A.M. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest 1991, 88:1237-1243.
22. Mariathasan S., Weiss D.S., Newton K., et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006, 440:228-232.
23. Martinon F., Mayor A., Tschopp J. The inflammasomes: Guardians of the body. Annu Rev Immunol 2009, 27:229-265.
24. Martinon F., Petrilli V., Mayor A., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
25. Masters S.L., Dunne A., Subramanian S.L., et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat Immunol 2010, 11:897-904.
26. McGonagle D., Tan A.L., Shankaranarayana S., et al. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007, 66:1683-1684.
27. Mitroulis I., Skendros P., Ritis K. Targeting IL-1beta in disease: The expanding role of NLRP3 inflammasome. Eur J Intern Med 2010, 21:157-163.
28. Pomerantz B.J., Reznikov L.L., Harken A.H., et al. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci USA 2001, 98:2871-2876.
29. Porter K.E., Turner N.A. Cardiac fibroblasts: At the heart of myocardial remodeling. Pharmacol Ther 2009, 123:255-278.
30. Rajamaki K., Lappalainen J., Oorni K., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: A novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5:e11765.
31. Shigeoka A.A., Mueller J.L., Kambo A., et al. An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury. J Immunol 2010, 185:6277-6285.
32. So A., De Smedt T., Revaz S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
33. Souders C.A., Bowers S.L., Baudino T.A. Cardiac fibroblast: The renaissance cell. Circ Res 2009, 105:1164-1176.
34. Steffens S., Montecucco F., Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009, 102:240-247.
35. Yajima N., Takahashi M., Morimoto H., et al. Critical role of bone marrow apoptosis-associated speck-like protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice. Circulation 2008, 117:3079-3087.
36. Yamamoto M., Yaginuma K., Tsutsui H., et al. ASC is essential for LPS-induced activation of procaspase-1 independently of TLR-associated signal adaptor molecules. Genes Cells 2004, 9:1055-1067.
37. Yamasaki K., Muto J., Taylor K.R., et al. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 2009, 284:12762-12771.
38. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-1135.
39. Zhao Z.Q., Lefer D.J., Sato H., et al. Monoclonal antibody to ICAM-1 preserves postischemic blood flow and reduces infarct size after ischemia-reperfusion in rabbit. J Leukoc Biol 1997, 62:292-300.
40. Zhou R., Tardivel A., Thorens B., et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010, 11:136-140.
41. Zhu P., Duan L., Chen J., et al. Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Hum Gene Ther 2011, 22:853-864.